DNTH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
761.0K
+64.4%
463.0K
+63.0%
284.0K
-28.3%
396.0K
+105.2%
193.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
761.0K
+64.4%
463.0K
+63.0%
284.0K
-28.3%
396.0K
+105.2%
193.0K
Operating Expenses
62.2M
+32.4%
47.0M
-32.7%
69.8M
+71.6%
40.7M
+15.8%
35.1M
R&D
48.7M
+41.0%
34.5M
-42.4%
59.9M
+84.4%
32.5M
+23.8%
26.3M
SG&A
13.6M
+8.7%
12.5M
+25.6%
9.9M
+21.2%
8.2M
-7.6%
8.9M
Operating Income
-61482000
-32.1%
-46533000
+33.1%
-69541000
-72.6%
-40288000
-15.3%
-34927000
EBITDA
-61445000
-32.1%
-46501000
+33.1%
-69514000
-72.7%
-40261000
-15.4%
-34897000
Net Income
-50215000
-23.0%
-40834000
+36.6%
-64432000
-75.3%
-36765000
-16.2%
-31629000
EPS (Basic)
$-0.90
-5.9%
$-0.85
+40.6%
$-1.43
-47.4%
$-0.97
-10.2%
$-0.88
EPS (Diluted)
$-0.90
-5.9%
$-0.85
+40.6%
$-1.43
-47.4%
$-0.97
-10.2%
$-0.88
Shares (Diluted)
56.0M
+16.6%
48.0M
+6.6%
45.1M
+19.2%
37.8M
+5.5%
35.8M
Dianthus Therapeutics (DNTH) โ€” Financials